Skip to main
AVXL

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences is poised for success as it works to strengthen its regulatory positioning and further develop its promising treatments for a variety of CNS disorders with high unmet need, including Alzheimer's disease, Parkinson's disease, and Rett syndrome. With additional clinical and biomarker data to address feedback from regulatory agencies and ongoing engagement with the FDA, the company is taking a strategic and disciplined approach to its development strategy. While the recent withdrawal in the EU introduces timing uncertainty, the company maintains its focus on advancing its treatments and has been encouraged by the EMA's SME Office. Our valuation reflects the potential of ANAVEX 2-73, with a $24.0 price target derived from a 30% discount rate and adjusted probabilities of success in the US and EU markets.

Bears say

Anavex Life Sciences is in the process of discussing with regulators to define a viable US regulatory pathway for their treatment in Alzheimer's disease, while also highlighting potential neuroprotective benefits of their drug in preserving brain volume according to recent data. This progress indicates a potential for future growth and improvement, although further studies and regulatory approvals are still necessary.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.